Genelux Corp reports results for the quarter ended June 30 - Earnings Summary
11/08/2025 22:01
Genelux Corp GNLX.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of six analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -24 cents to -20 cents per share. Reported revenue was zero; analysts expected zero. Genelux Corp's reported EPS for the quarter was a loss of 20 cents. The company reported a quarterly loss of $7.46 million. Genelux Corp shares had risen by 9.8% this quarter and gained 33.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 3.2% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Genelux Corp is $13.00, about 75.8% above its last closing price of $3.15 This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.21 | -0.20 | Beat |
| Mar. 31 2025 | -0.24 | -0.21 | Beat |
| Dec. 31 2024 | -0.18 | -0.26 | Missed |
| Sep. 30 2024 | -0.19 | -0.19 | Met |
Recent news on Genelux
See all newsGenelux posts wider-than-expected Q2 loss on higher R&D expenses
Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview
Genelux Q1 net loss widens, misses analyst expectations
Brief: Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock
Brief: Genelux Corporation Announces Proposed Public Offering of Common Stock